Boston Scientific's Watchman Heart Implant Shines in Clinical Trial

Piper Sandler reaffirms Overweight rating, expects 20% annual sales growth for the device

Apr. 19, 2026 at 8:50pm

Got story updates? Submit your updates here. ›

A close-up macro photograph of the complex mechanical components and precision engineering of a Boston Scientific Watchman heart implant device, conveying the advanced medical technology behind this life-saving cardiac device.The advanced engineering and precision manufacturing behind Boston Scientific's Watchman heart implant device, a critical tool for reducing stroke risk in patients with heart rhythm disorders.Boston Today

Boston Scientific's Watchman heart implant met all primary and secondary endpoints in the Champion-AF clinical study, evaluating the device as a first-line treatment option for stroke risk reduction. Piper Sandler reaffirmed its Overweight rating on Boston Scientific stock, expecting Watchman sales to increase 20% annually for the next several years and contribute around 200 basis points to the company's topline growth.

Why it matters

The Watchman device has the potential to benefit the over 59 million people globally with a heart rhythm disorder. Boston Scientific's strong performance in 2025, with 19.9% net sales growth to $20 billion and adjusted EPS of $3.06, demonstrates the company's ability to capitalize on this market opportunity.

The details

In the Champion-AF study, Boston Scientific's Watchman heart implant met all primary and secondary endpoints regarding safety and efficiency. The study evaluated the Watchman device as a first-line treatment option for stroke risk reduction. Piper Sandler expects Watchman sales to increase 20% annually for the next several years, contributing around 200 basis points to Boston Scientific's topline growth.

  • The Champion-AF study results were released on April 6, 2026.
  • In 2025, Boston Scientific's net sales grew 19.9% to $20 billion, and adjusted EPS came to $3.06.

The players

Boston Scientific Corp

An American multinational biotechnology and biomedical engineering company that makes medical devices used to address cardiovascular, respiratory, and neurological conditions. Boston Scientific was founded in 1979 and is based in Massachusetts.

Mike Mahoney

The CEO of Boston Scientific, who said 2025 was another exceptional year for the company, noting that they exceeded their goals.

Piper Sandler

An investment bank that reaffirmed its Overweight rating on Boston Scientific stock and expects Watchman sales to increase 20% annually for the next several years.

Got photos? Submit your photos here. ›

What they’re saying

“In 2025, Boston Scientific's net sales grew 19.9% to $20 billion, and adjusted EPS came to $3.06, compared to $2.51 in the prior year. Boston Scientific CEO Mike Mahoney said 2025 was another exceptional year for the company, noting that they exceeded their goals.”

— Mike Mahoney, CEO, Boston Scientific

What’s next

The company expects the growth to continue, forecasting topline growth of at least 10.5% in 2026.

The takeaway

Boston Scientific's Watchman heart implant has shown strong clinical results, and the company's overall performance in 2025 demonstrates its ability to capitalize on the market opportunity for devices that address heart rhythm disorders. The positive outlook for Watchman sales growth and the company's continued topline expansion suggest Boston Scientific is well-positioned to maintain its leadership in the medical device industry.